Today's story goes like this: AstraZeneca has snared Martin Mackay to head up its global R&D organization. Mackay, of course, previously was head of Pfizer PharmaTherapeutics, responsible for Pfizer’s small molecules program and on the company’s executive leadership team.
He led half of Pfizer's R&D engine; the other half was led by Mikael Dolsten, who until today was head of Pfizer BioTherapeutics and Vaccines R&D. Before that Dolsten was head of Wyeth R&D - now he's head of Pfizer's worldwide R&D.
Following so far?
In honor of this big R&D day, BioPharma Today has dug into the Elsevier Business Intelligence vaults and pulled out an exclusive interview for your listening pleasure.
Imagine: It is April 2009. Pfizer has just announced its new R&D structure, post Wyeth merger. Pfizer's Martin Mackay and Mikael Dolsten sit down with our editors from IN VIVO to explain how it's going to work. Want to know what makes Mackay or Dolsten tick?
To access this complimentary podcast, click here.
Want more? Check out our coverage of Mackay's big move and Dolsten's promotion in "The Pink Sheet" Daily. Not a subscriber? Click here for a free trial.
